ORCID as entered in ROS

Select Publications
2007, 'Opioid deaths can occur in patients with naltrexone implants', Medical Journal of Australia, 186, pp. 152 - 153
,2007, 'Opioid overdose deaths can occur in patients with naltrexone implants', Medical Journal of Australia, 186, pp. 152 - 153
,2007, 'Opioid overdose deaths can occur in patients with naltrexone implants - In reply', Medical Journal of Australia, 187, pp. 56 - 57
,2007, 'Prevalence and correlates of cannabis use in developed and developing countries', Current Opinion in Psychiatry, 20, pp. 393 - 397
,2007, 'Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research', Addiction, 102, pp. 1685 - 1688
,2007, 'Response to letters: Opioid deaths can occur in patients with naltrexone implants', Medical Journal of Australia, 187, pp. 56 - 57
,2007, 'UK classification of cannabis: is a change needed and why?', Lancet, 370, pp. 1541 - 1541
,2006, 'Assessing the wisdom of funding DrinkWise', Medical Journal of Australia, 185, pp. 635 - 636, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00736.x
,2006, ''Occasional' and 'social' smokers: Potential target groups for smoking cessation campaigns?', Australian and New Zealand Journal of Public Health, 30, pp. 550 - 554, http://dx.doi.org/10.1111/j.1467-842X.2006.tb00784.x
,2006, 'Delivering on the promise of human stem-cell research. What are the real barriers?', EMBO Reports, 7, pp. 1188 - 1192, http://dx.doi.org/10.1038/sj.embor.7400861
,2006, 'Strong and weak lifespan extension: What is most feasible and likely?', Australasian Journal on Ageing, 25, pp. 58 - 62, http://dx.doi.org/10.1111/j.1741-6612.2006.00150.x
,2006, 'What does the community think about lifespan extension technologies? The need for an empirical base for ethical and policy debates', Australasian Journal on Ageing, 25, pp. 180 - 184, http://dx.doi.org/10.1111/j.1741-6612.2006.00173.x
,2006, 'Avoiding potential misuses of addiction brain science', Addiction, 101, pp. 1529 - 1532, http://dx.doi.org/10.1111/j.1360-0443.2006.01604.x
,2006, 'How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?', Australian and New Zealand Journal of Psychiatry, 40, pp. 941 - 950, http://dx.doi.org/10.1111/j.1440-1614.2006.01917.x
,2006, 'Ensuring that addiction science is deserving of public trust', Addiction, 101, pp. 1223 - 1224, http://dx.doi.org/10.1111/j.1360-0443.2006.01552.x
,2006, 'How have the SSRI antidepressants affected suicide risk?', Lancet, 367, pp. 1959 - 1962, http://dx.doi.org/10.1016/S0140-6736(06)68860-0
,2006, 'The regulatory challenges in engineering a safer tipple', Journal of Psychopharmacology, 20, pp. 321 - 322, http://dx.doi.org/10.1177/0269881106063047
,2006, 'Dissecting the causal anatomy of the link between cannabis and other illicit drugs', Addiction, 101, pp. 472 - 473, http://dx.doi.org/10.1111/j.1360-0443.2006.01427.x
,2006, 'Ethical eye: Drug addiction', ADDICTION, 101, pp. 460 - 461, http://dx.doi.org/10.1111/j.1360-0443.2006.01417.x
,2006, 'Cannabis use and the mental health of young people', Australian and New Zealand Journal of Psychiatry, 40, pp. 105 - 113, http://dx.doi.org/10.1111/j.1440-1614.2006.01756.x
,2006, 'The metabolic syndrome: Recognition and management', Disease Management, 9, pp. 16 - 33, http://dx.doi.org/10.1089/dis.2006.9.16
,2006, 'Is cannabis use psychotogenic?', Lancet, 367, pp. 193 - 195, http://dx.doi.org/10.1016/S0140-6736(06)68012-4
,2006, 'Minimising research censorship by government funders', International Journal of Drug Policy, 17, pp. 240 - 241, http://dx.doi.org/10.1016/j.drugpo.2006.02.003
,2006, 'Stereotactic neurosurgical treatment of addiction: Minimizing the chances of another 'great and desperate cure'', Addiction, 101, pp. 1 - 3, http://dx.doi.org/10.1111/j.1360-0443.2005.01363.x
,2006, 'Canadian heroin supply and the australian `heroin shortage`', Addiction, 101, pp. 1667 - 1668
,2006, 'Is cannabis use a contributory cause of psychosis?', Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie, 51, pp. 556 - 565
,2006, 'The ethics of paying drug users who participate in research: A review and practical recommendations', JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 1, pp. 21 - 35, http://dx.doi.org/10.1525/jer.2006.1.4.21
,2006, 'The evidence base for registration and reimbursement of new pharmaceuticals in cancer treatment: surrogate and real health outcomes', Asia-Pacific Journal of Clinical Oncology, 2, pp. 119 - 121
,2006, 'What are the policy implications of the evidence on cannabis and psychosis?', Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie, 51, pp. 566 - 574
,2005, 'The metabolic syndrome', Ethnicity and Disease, 15, pp. 1 - 2
,2005, 'Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?', Plos Medicine, 2, pp. 0860 - 0863, http://dx.doi.org/10.1371/journal.pmed.0020266
,2005, 'British drinking: A suitable case for treatment?', BMJ, 331, pp. 527, http://dx.doi.org/10.1136/bmj.331.7516.527
,2005, 'Being realistic about benefits of supervised injecting facilities', Lancet, 366, pp. 271 - 272, http://dx.doi.org/10.1016/S0140-6736(05)66476-8
,2005, 'The integrity of the science base: A test case', Addiction, 100, pp. 581 - 584, http://dx.doi.org/10.1111/j.1360-0443.2005.01109.x
,2005, 'Who wants to live forever?', EMBO Reports, 6, pp. 98 - 102, http://dx.doi.org/10.1038/sj.embor.7400339
,2005, 'Cannabinoids and cancer: Causation, remediation, and palliation', Lancet Oncology, 6, pp. 35 - 42, http://dx.doi.org/10.1016/s1470-2045(04)01711-5
,2005, 'Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs', Drug and Alcohol Review, 24, pp. 39 - 48, http://dx.doi.org/10.1080/09595230500126698
,2005, 'The prospects for tobacco harm reduction', International Journal of Drug Policy, 16, pp. 139 - 142, http://dx.doi.org/10.1016/j.drugpo.2005.04.002
,2005, 'Age differentials in the impacts of reduced heroin: Effects of a `heroin shortage` in NSW, Australia', Drug and Alcohol Dependence, 79, pp. 397 - 404, http://www.sciencedirect.com/science/article/B6T63-4G94HV1-1/2/12ce425f6d4829bab75c04f227f1669f
,2005, 'Tailoring access to high cost, genetically targeted drugs', Medical Journal of Australia, 182, pp. 607 - 608
,2005, 'The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia', BMC Public Health, 5
,2004, 'Feeling 'better than well'', EMBO Reports, 5, pp. 1105 - 1109, http://dx.doi.org/10.1038/sj.embor.7400303
,2004, 'New treatments for addiction: Behavioural, ethical, legal and social questions', ADDICTION, 99, pp. 1481 - 1481, http://dx.doi.org/10.1111/j.1360-0443.2004.00924.x
,2004, 'An invitation to an alcohol industry lobby to help decide public funding of alcohol research and professional training: A decision that should be reversed', Addiction, 99, pp. 1235 - 1236, http://dx.doi.org/10.1111/j.1360-0443.2004.00873.x
,2004, 'Footnotes to hall (2004) - Reply to Wodak', ADDICTION, 99, pp. 1064 - 1064, http://dx.doi.org/10.1111/j.1360-0443.2004.00825.x
,2004, 'Footnotes to Hall (2004) [2] (multiple letters)', Addiction, 99, pp. 1063 - 1064, http://dx.doi.org/10.1111/j.1360-0443.2004.00817.x
,2004, 'The contribution of research to Australian policy responses to heroin dependence 1990-2001: A personal retrospection', Addiction, 99, pp. 560 - 569, http://dx.doi.org/10.1111/j.1360-0443.2004.00717.x
,2004, 'Retrospections of a recovering drug researcher', Addiction, 99, pp. 153 - 154, http://dx.doi.org/10.1111/j.1360-0443.2003.00613.x
,2004, 'Distribution of major health risks: Findings from the global burden of disease study', Plos Medicine, 1, pp. 044 - 055, http://dx.doi.org/10.1371/journal.pmed.0010027
,2004, 'Genetic screening for susceptibility to depression: Can we and should we?', Australian and New Zealand Journal of Psychiatry, 38, pp. 73 - 80, http://dx.doi.org/10.1111/j.1440-1614.2004.01300.x
,